NCT06589713View on ClinicalTrials.gov

Effect of Renal Impairment on Enpatoran Pharmacokinetics

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

April 22, 2026

Study Completion Date

April 22, 2026

Conditions
Renal Impairment
Interventions
DRUG

Enpatoran

Participants will receive a single oral dose of enpataron tablets once daily.

Trial Locations (1)

24105

RECRUITING

CRS Clinical Research Services Kiel GmbH, Kiel

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY